文献速递慢阻肺

25-羟基维生素D水平与COPD肺功能及急性加重结局的关联:SPIROMICS队列分析

Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort.
PubMed 文献 · Chest · 2020-01-17

基于SPIROMICS队列1609例COPD患者,分析基线25-羟基维生素D与肺功能及急性加重的关联。维生素D缺乏(<20 ng/mL)占21%,与较低基线FEV1%预计值、1年内FEV1下降更快及既往1年任何急性加重风险升高独立相关。25-羟基维生素D水平可能是COPD不良结局的潜在标志物。

要点

  • 维生素D缺乏与COPD患者基线FEV1%预计值低4.11%独立相关。
  • 维生素D缺乏与1年内FEV1下降速率增加1.27%预计值/年相关。
  • 维生素D缺乏与既往1年任何急性加重风险升高相关(OR 1.32)。

核心结论

  • 维生素D缺乏与COPD患者更差的横断面及纵向肺功能以及既往急性加重风险增加相关。
  • 25-羟基维生素D水平可能是COPD不良结局的潜在标志物。

研究设计与样本

  • 基于SPIROMICS队列,测量1609例COPD参与者储存样本的血清25-羟基维生素D水平。
  • 25-羟基维生素D按连续变量及二分类(缺乏<20 ng/mL vs 不缺乏≥20 ng/mL)建模。
  • 结局包括当前及1年纵向FEV1%预计值下降,以及既往1年和随访第一年任何及严重COPD急性加重。

主要发现

  • 维生素D缺乏在队列中占21%,在较年轻者、活跃吸烟者和黑人中更常见。
  • 维生素D缺乏与入组时FEV1%预计值低4.11%独立相关(95% CI -6.90%至-1.34%;P=.004)。
  • 维生素D缺乏与1年后FEV1下降速率增加1.27%预计值/年相关(95% CI -2.32%至-0.22%;P=.02)。
  • 维生素D缺乏与既往1年任何COPD急性加重风险升高相关(OR 1.32;95% CI 1.00-1.74;P=.049)。
  • 25-羟基维生素D每降低10 ng/mL与基线肺功能低1.04%预计值(95% CI -1.96%至-0.12%;P=.03)及入组前1年任何急性加重风险升高相关(OR 1.11;95% CI 1.01-1.22;P=.04)。

关键数值与推荐

  • 维生素D缺乏定义为25-羟基维生素D<20 ng/mL,不缺乏定义为≥20 ng/mL。

临床怎么用

  • 可考虑将25-羟基维生素D水平作为COPD患者不良结局风险评估的潜在标志物。
  • 对维生素D缺乏的COPD患者应关注肺功能下降及急性加重风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The relationship between 25-hydroxyvitamin D (25-OH-vitamin D) and COPD outcomes remains unclear. Using the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), we determined associations among baseline 25-OH-vitamin D and cross-sectional and longitudinal lung function and COPD exacerbations. METHODS: Serum 25-OH-vitamin D level was measured in stored samples from 1,609 SPIROMICS participants with COPD. 25-OH-vitamin D levels were modeled continuously and dichotomized as deficient (< 20 ng/mL) vs not deficient (≥ 20 ng/mL). Outcomes of interest included % predicted FEV1 (current and 1-year longitudinal decline) and COPD exacerbations (separately any and severe, occurring in prior year and first year of follow-up). RESULTS: Vitamin D deficiency was present in 21% of the cohort and was more prevalent in the younger, active smokers, and blacks. Vitamin D deficiency was independently associated with lower % predicted FEV1 (by 4.11%) at enrollment (95% CI, -6.90% to -1.34% predicted FEV1; P = .004), 1.27% predicted greater rate of FEV1 decline after 1 year (95% CI, -2.32% to -0.22% predicted/y; P = .02), and higher odds of any COPD exacerbation in the prior year (OR, 1.32; 95% CI, 1.00-1.74; P = .049). Each 10-ng/mL decrease in 25-OH-vitamin D was associated with lower baseline lung function (-1.04% predicted; 95% CI, -1.96% to -0.12% predicted; P = .03) and increased odds of any exacerbation in the year before enrollment (OR, 1.11; 95% CI, 1.01-1.22; P = .04). CONCLUSIONS: Vitamin D deficiency is associated with worse cross-sectional and longitudinal lung function and increased odds of prior COPD exacerbations. These findings identify 25-OH-vitamin D levels as a potentially useful marker of adverse COPD-related outcomes.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Burkes RM, Ceppe AS, Doerschuk CM, et al. Associations Among 25-Hydroxyvitamin D Levels, Lung Function, and Exacerbation Outcomes in COPD: An Analysis of the SPIROMICS Cohort. Chest. 2020. PMID: 31958447. doi:10.1016/j.chest.2019.11.047

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。